These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 25224382)

  • 1. Long-lasting uveitis remission and hearing loss recovery after rituximab in Vogt-Koyanagi-Harada disease.
    Caso F; Rigante D; Vitale A; Costa L; Bascherini V; Latronico E; Franceschini R; Cantarini L
    Clin Rheumatol; 2015 Oct; 34(10):1817-20. PubMed ID: 25224382
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bilateral dexamethasone intravitreal implant in a young patient with Vogt-Koyanagi-Harada disease and refractory uveitis.
    Latronico ME; Rigante D; Caso F; Cantarini L; Costa L; Nieves-Martín L; Traversi C; Franceschini R
    Clin Rheumatol; 2015 Jun; 34(6):1145-8. PubMed ID: 24763751
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Sensorineural hearing loss evolution in Vogt-Koyanagi-Harada syndrome].
    Rodríguez Rivera V; Garrigues HP; Gallego Pinazo R
    Acta Otorrinolaringol Esp; 2011; 62(6):465-8. PubMed ID: 21167466
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of B Cell Depletion Therapy with Rituximab in Refractory Chronic Recurrent Uveitis Associated with Vogt-Koyanagi-Harada Disease.
    Abu El-Asrar AM; Dheyab A; Khatib D; Struyf S; Van Damme J; Opdenakker G
    Ocul Immunol Inflamm; 2022 Apr; 30(3):750-757. PubMed ID: 32990482
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rituximab for sight-threatening refractory pediatric Vogt-Koyanagi-Harada disease.
    Umran RMR; Shukur ZYH
    Mod Rheumatol; 2018 Jan; 28(1):197-199. PubMed ID: 26154298
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of intravitreal dexamethasone implant in patients with Vogt-Koyanagi-Harada Disease and bilateral panuveitis: Two case reports.
    Chen PL; Chen SN
    Medicine (Baltimore); 2021 Oct; 100(40):e27394. PubMed ID: 34622843
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyclosporin therapy in Vogt Koyanagi Harada disease.
    Wakefield D; McCluskey P; Reece G
    Aust N Z J Ophthalmol; 1990 May; 18(2):137-42. PubMed ID: 2390240
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The outcomes of mycophenolate mofetil therapy combined with systemic corticosteroids in acute uveitis associated with Vogt-Koyanagi-Harada disease.
    Abu El-Asrar AM; Hemachandran S; Al-Mezaine HS; Kangave D; Al-Muammar AM
    Acta Ophthalmol; 2012 Dec; 90(8):e603-8. PubMed ID: 22971163
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systemic corticosteroid treatment in Vogt-Koyanagi-Harada disease.
    Hayasaka S; Okabe H; Takahashi J
    Graefes Arch Clin Exp Ophthalmol; 1982; 218(1):9-13. PubMed ID: 7056483
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Vogt-Koyanagi-Harada syndrome. Eight cases].
    Alaoui FZ; Benamour S; El Kabli H; Amraoui A
    Rev Med Interne; 2007 Apr; 28(4):250-4. PubMed ID: 17350144
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Long-term course of immunosuppressive therapy of Vogt-Koyanagi-Harada syndrome].
    Wand K; Abraham S; Loos D; Stumpfe S; Lohmann C; Maier M; Feucht N
    Ophthalmologe; 2015 Oct; 112(10):857-60. PubMed ID: 25680347
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mycophenolate mofetil combined with systemic corticosteroids prevents progression to chronic recurrent inflammation and development of 'sunset glow fundus' in initial-onset acute uveitis associated with Vogt-Koyanagi-Harada disease.
    Abu El-Asrar AM; Dosari M; Hemachandran S; Gikandi PW; Al-Muammar A
    Acta Ophthalmol; 2017 Feb; 95(1):85-90. PubMed ID: 27535102
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An unusual cause of vertigo, tinnitus, and hyperacusis: Vogt-Koyanagi-Harada syndrome.
    Gaudreau P; Moy J; Lindsay F
    Ear Nose Throat J; 2012 Dec; 91(12):E7-9. PubMed ID: 23288830
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bilateral Cochlear Implantation in Vogt-Koyanagi-Harada Syndrome: A Case Report.
    AlHelali N; Hajr E; Almuhawas F; Hagr A
    Otol Neurotol; 2019 Aug; 40(7):e694-e697. PubMed ID: 31219962
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Studies on corticosteroid therapy in Vogt-Koyanagi-Harada disease.
    Sasamoto Y; Ohno S; Matsuda H
    Ophthalmologica; 1990; 201(3):162-7. PubMed ID: 2089358
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reversal of Peripheral Iris Depigmentation Associated with Vogt-Koyanagi-Harada Disease.
    Tobaigy MF; AlBloushi AF; Al-Dhibi HA
    Ocul Immunol Inflamm; 2024 May; 32(4):424-428. PubMed ID: 36657743
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Repeated pulse corticosteroid therapy in Vogt-Koyanagi-Harada disease. A case report].
    Denoyer A; Le Lez ML; Arsène S; Pisella PJ
    J Fr Ophtalmol; 2004 Apr; 27(4):404-8. PubMed ID: 15173651
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Vogt Koyanagi Harada syndrome. Report of a case with hearing loss, tinnitus, vertigo associated to uveitis].
    Pino Rivero V; Pardo Romero G; Rodríguez Carmona M; Iglesias González RJ; del Castillo Beneyto F
    An Otorrinolaringol Ibero Am; 2007; 34(3):281-5. PubMed ID: 17725172
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A case presentation of an IgA nephropathy patient with Vogt-Koyanagi-Harada syndrome.
    Zhang Q; Fan X; Tian M; Han H
    BMC Nephrol; 2020 Jul; 21(1):272. PubMed ID: 32660433
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Triple agent immunosuppressive therapy in Vogt-Koyanagi-Harada syndrome.
    Agarwal M; Ganesh SK; Biswas J
    Ocul Immunol Inflamm; 2006 Dec; 14(6):333-9. PubMed ID: 17162603
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.